What is TNGX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 4.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TNGX?

P/E (TTM) is n/a and 52-week range is $6.69 to $34.39 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TNGX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TNGX?

The company profile lists revenue (TTM) near $58M, net income (TTM) near $-8.81B, EPS (TTM) near $-0.84 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Tango Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 162.3M shares outstanding, ISIN US87583X1090 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Tango Therapeutics Inc

$TNGX

Health Care · Biotechnology

IR Run Scenarios

$23.81

+5.49%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. The company is headquartered in Boston, Massachusetts and currently employs 137 full-time employees. The company went IPO on 2020-09-03. The firm's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The firm is focused on clinical development of two methylthioadenosine phosphorylase (MTAP)-deleted selective PRMT5 inhibitors: vopimetostat (TNG462) for non-CNS cancers, both as a monotherapy and in combination with RAS inhibitors, and TNG456, brain-penetrant protein arginine methyltransferase 5 (PRMT5) inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of the Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.

Employees

137

Website

www.tangotx.com/

IPO

2020-09-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)